Contact us


Diagonal 123, 11th floor

08005 Barcelona (Spain)

Report on suspected adverse drug reactions

Pharmacovigilance Telephone (24/7)

+34 936 110 914

Please feel free to use the following form to get in contact with us:
* Required

Data Protection: GALENICUM HEALTH S.L.U. Will process the data to meet your requests for information through our contact form and email, legitimized by the consent you give us when contacting us. You can exercise your rights at Learn about our privacy policy by clicking here.

Thanks for reaching out. We will get back to you as soon as possible.


The information contained in this section is aimed at the healthcare professional of the Pharmaceutical Industry, therefore, specialized training is required for its correct interpretation.

The products mentioned may have a different authorized data sheet in each country.

If you click the "accept" button, you are expressing your willingness to access the information explicitly intended for healthcare professionals.


DEVELOPMENT OF THE FIRST GENERIC PHARMACEUTICAL SPECIALTY WITH DABIGATRAN. Decision EMC/2755/2017, dated November 20, (DOGC núm. 7508 of 30/11/2017) regarding the call for NUCLEUS OF INDUSTRIAL RESEARCH AND EXPERIMENTAL DEVELOPMENT (file number RD17-1-0006). This project has received funding from the European Union through the European Regional Development Fund (ERDF). With the collaboration from ACCIÓ.